November 26, 2021
NICE has issued updated guidance on the management of type 2 diabetes (T2D) in adults, which include new recommendations on the treatment of T2D in patients with chronic kidney disease (CKD).
The 2021 recommendations advise that patients with CKD and T2D and an albumin-to-creatinine ratio (ACR) of 3 mg/mmol or more should be offered an angiotensin receptor blocker (ARB) or an angiotensin‑converting enzyme (ACE) inhibitor, titrated to the highest licensed and tolerated dose.
For CKD patients who are already receiving an ARB or an ACE inhibitor at the highest licensed tolerated dose, an SGLT2 inhibitor should be offered in addition to the ARB or ACE inhibitor if their ACR is at least 30 mg/mmol and meet the prescribing criteria, including eGFR thresholds.
NICE also advises that SGLT2 inhibitors can be considered for patients with an ACR of between 3 and 30 mg/mmol, however these drugs may not be suitable for all patients in this group.
The recommendations follow the publication of strong evidence from randomised controlled trials which showed that SGLT2 inhibitors reduced the risk of CKD progression, mortality and cardiovascular events in adults with T2D. Economic modelling found that SGLT2 inhibitors were likely to be both more effective and cost saving than standard treatment for people with an ACR above 30 mg/mmol at baseline.
The NICE appraisal committee determined that people with a baseline ACR of 3 to 30 mg/mmol will experience fewer cardiovascular events and events relating to chronic kidney disease progression than people with a higher ACR. Because of this, SGLT2 inhibitors would prevent fewer events for this group in absolute terms, even if the relative effect was the same. Economic modelling showed that SGLT2 inhibitors were still likely to be both more effective and cost saving in people with a baseline ACR of between 3 and 30 mg/mol compared with standard treatment.
The guideline calls for research on the effectiveness of SGLT2 inhibitors for people with a baseline ACR less than 3 mg/mmol as there is no evidence looking specifically at this group.
Draft recommendations have also been published on the diagnosis and management of adults with type 1 diabetes.
The draft guidance advises that age or BMI alone should not be used to exclude type 1 diabetes. It must be kept in mind that other diabetes subtypes may be present and the diagnosis of type 1 disease should be reviewed at clinical reviews.
Diabetes-specific autoantibodies should be measured at the time of diagnosis, bearing in mind that these tests have the lowest rate of false negatives at that time. Serum C-peptide should not routinely be used to confirm a diagnosis of type 1 diabetes, however, in people with a negative diabetes-specific autoantibody result, and uncertain diabetes classification, non-fasting serum C-peptide can be used with a paired blood glucose. Serum C-peptide measurement can also be used to revisit the diabetes classification if there is doubt about the type 1 diagnosis, being mindful that the discriminative value of serum C-peptide to diagnose type 1 diabetes increases the longer the test is conducted after initial diagnosis.
The guidance now recommends that patients should be offered a choice of real-time continuous glucose monitoring (CGM) or intermittently scanned continuous glucose monitoring (isCGM) based on their needs and preferences. The cheapest device should be offered in the first instance. If a person is unable or does not wish to use any real-time CGM or isCGM device, capillary blood glucose monitoring should be used.
NICE has also published draft guidance on the diagnosis of type 1 and 2 diabetes in children and young people.
The guidance includes updated recommendations on CGM for this age group. It is now recommended that all children and young people with type 1 diabetes be offered real-time CGM, accompanied by education. Paediatric patients (aged ≥4 years) who are unable or prefer not to use real-time CGM should be offered isCGM. Patients should be offered a choice of real-time CGM device.
Factors to consider when choosing a device include whether the device provides predictive alerts or alarms and whether these need to be shared with anyone else, the ease of use (including for people with limited dexterity), and how often the device needs to be calibrated. It is also important to consider patient factors, including their insulin regimen and type of insulin pump, as not all devices integrate with pumps as part of a hybrid closed loop or insulin suspend function. Other factors to consider include sports participation, device sensitivity and cosmetic aspects.
If a child or young person is unable or does not wish to use any real-time CGM or isCGM device, capillary blood glucose monitoring should be offered.
The draft guidance includes a number of key recommendations for research, including the effectiveness and cost effectiveness of CGM in children and young people with type 2 diabetes, and the best CGM sensor adhesive to prevent sensitivities.
Both the draft guidance on type 1 diabetes in adults and in children are now open for public consultation. The closing date for receipt of comments is 22 December 2021. The final recommendations are expected to be published at the end of March next year.
© 2021 WebMD, LLC
Send comments and news tips to firstname.lastname@example.org.
Cite this: Dawn O’Shea. NICE Updates Recommendation on the Management of Diabetes – Medscape – Nov 26, 2021.
Dawn O’Shea is a freelance writer for Univadis from Medscape.
You have already selected for My Alerts
Click the topic below to receive emails when new articles are available.
You’ve successfully added to your alerts. You will receive email when new content is published.
Florastor vs. Align probiotics: Which is better? – Chicago Tribune
Masaba Gupta 'Swears By' This Healthy Drink; Shares Its Health Benefits – NDTV Food
Apart from being an ace fashion designer, Masaba Gupta is a hardcore foodie. She advocates clean eating habits. And, at times, she also shares glimpses from her healthy meal diaries. Today, Masaba decided to talk about safed petha juice. Masaba posted a snapshot of a glass filled with the juice on Instagram Stories and wrote about its benefits. Masaba said that she often ends up asking herself this – “Are we uselessly chasing weight loss, when we should actually be chasing an alkaline body?”
Masaba Gupta further explained that Ayurveda “pushes you to have an alkaline system. And, it does wonders”. She compared it with the benefits of having safed petha (Winter melon, Ash gourd) juice on an empty stomach. Masaba went to add, “I am a pitta type and I break my fast with it now.” Listing the benefits of the juice, Masaba said that the drink is a diuretic and helps relieve sciatica pain. It also cleans the small and large intestines and has anti-ageing properties. Best part? It cools the body. She then advised, “Drink as is or with a pinch of black jaggery or salt. See if it works.” Masaba also added the hashtag “Masaba swears by,” to her Stories.
Take a look:
Seems like Masaba Gupta has been consuming all things healthy of late. On Sunday, she shared a picture of jujube fruit on her Instagram Stories. She captioned the post as, “Ber, jujube fruit or Chinese date – call whatever you want – many names, many benefits.” The designer explained the benefits of the first which include sound sleep, better digestion, anti-inflammatory properties, and vitamins B and C (glowing skin). She stated, “It’s a blood purifier, contains 18 of the 24 essential amino acids the body needs to stay healthy and helps reduce stress. It’s in season now and eating seasonal fruit is the best thing you can do for your body.”
Healthy juices make Masaba Gupta happy. And, we have proof. Some days back, she dropped a picture of her healthy glass of drink. Masaba simply captioned it saying, “Warm water, lemon, basil seeds (sabja).”
How To?2 months ago
Register now for winter-spring 2022 ORICL courses – Oak Ridge Today
How To?2 months ago
News blog, November 18: Nearly all restrictions to stop from 11.59pm; an Everest challenge for a good cause – Shepparton News
Mobile3 weeks ago
Pixel 6 looks to debut the Gboard ‘Assistant voice typing’ experience first demoed at I/O 2019 – 9to5Google
How To?2 months ago
How to use technology in your life? – The Times of India Blog
Games2 months ago
Coin-Op Management Sim Arcade Paradise Teases Minigames in PS5, PS4 Trailer – Push Square
Games2 months ago
Amazon Games switches off New World's entire economy after players discover duping glitch – PC Gamer
Games3 weeks ago
PS5 Stock: Where to Buy PlayStation 5 and When in January 2022 – Push Square
Tech3 months ago
Facebook is now Meta! Metaverse good or bad?